Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36521352)

  • 21. Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.
    Kelkar SS; Prabhu VS; Zhang J; Ogando YM; Roney K; Verma RP; Miles N; Marth C
    Arch Gynecol Obstet; 2024 Jun; 309(6):2833-2841. PubMed ID: 38634898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
    Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
    Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer.
    Post CCB; Stelloo E; Smit VTHBM; Ruano D; Tops CM; Vermij L; Rutten TA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Nout RA; Crosbie EJ; Powell ME; Mileshkin L; Leary A; Bessette P; Putter H; de Boer SM; Horeweg N; Nielsen M; Wezel TV; Bosse T; Creutzberg CL
    J Natl Cancer Inst; 2021 Sep; 113(9):1212-1220. PubMed ID: 33693762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study.
    Yao YC; Jin Y; Lei XF; Wang ZX; Zhang DS; Wang FH; Li YH; Xu RH; Wang F
    J Cancer; 2022; 13(9):2912-2921. PubMed ID: 35912009
    [No Abstract]   [Full Text] [Related]  

  • 25. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
    Konstantinopoulos PA; Luo W; Liu JF; Gulhan DC; Krasner C; Ishizuka JJ; Gockley AA; Buss M; Growdon WB; Crowe H; Campos S; Lindeman NI; Hill S; Stover E; Schumer S; Wright AA; Curtis J; Quinn R; Whalen C; Gray KP; Penson RT; Cannistra SA; Fleming GF; Matulonis UA
    J Clin Oncol; 2019 Oct; 37(30):2786-2794. PubMed ID: 31461377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Clinic Experience.
    Coston T; Desai A; Babiker H; Sonbol MB; Chakrabarti S; Mahipal A; McWilliams R; Ma WW; Bekaii-Saab TS; Stauffer J; Starr JS
    JCO Precis Oncol; 2023 Aug; 7():e2200706. PubMed ID: 37625102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer.
    Pacholczak-Madej R; Bartoletti M; Musacchio L; Püsküllüoglu M; Blecharz P; Lorusso D
    Expert Rev Anticancer Ther; 2024 Jun; ():. PubMed ID: 38863432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Usefulness of immunohistochemistry for mismatch repair protein and microsatellite instability examination in adenocarcinoma and background endometrium of sporadic endometrial cancer cases.
    Saeki H; Hlaing MT; Horimoto Y; Kajino K; Ohtsuji N; Fujino K; Terao Y; Hino O
    J Obstet Gynaecol Res; 2019 Oct; 45(10):2037-2042. PubMed ID: 31307113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
    Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
    Front Immunol; 2019; 10():3023. PubMed ID: 31998307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Treatment Patterns and Clinical Outcomes for Standard of Care Regimens in Patients with Deficient MMR or MSI-High Metastatic Colorectal and Non-Colorectal Cancer: A Retrospective Chart Review Study in France.
    Roset M; Amonkar M; Patel R; Lara N; Kothari S
    Adv Ther; 2022 Mar; 39(3):1215-1229. PubMed ID: 35025060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
    Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
    Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer.
    Ukkola I; Nummela P; Pasanen A; Kero M; Lepistö A; Kytölä S; Bützow R; Ristimäki A
    Virchows Arch; 2021 Sep; 479(3):471-479. PubMed ID: 33755781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study.
    Gatius S; Velasco A; Varela M; Cuatrecasas M; Jares P; Setaffy L; Bonhomme B; Santon A; Lindemann K; Croce S; Davidson B; Lax S; Palacios J; Matias-Guiu X
    Virchows Arch; 2022 May; 480(5):1031-1039. PubMed ID: 35124717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
    Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting.
    Malapelle U; Parente P; Pepe F; De Luca C; Pisapia P; Sgariglia R; Nacchio M; Gragnano G; Russo G; Conticelli F; Bellevicine C; Vigliar E; Iaccarino A; Covelli C; Balistreri M; Clemente C; Perrone G; Danza A; Scaramuzzi F; Fassan M; Troncone G; Graziano P
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer".
    Gadducci A; Cosio S
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity.
    Danaher P; Warren S; Ong S; Elliott N; Cesano A; Ferree S
    J Immunother Cancer; 2019 Jan; 7(1):15. PubMed ID: 30665466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors.
    Mestrallet G; Brown M; Bozkus CC; Bhardwaj N
    Front Immunol; 2023; 14():1210164. PubMed ID: 37492581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
    Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F
    Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.